Primary Colorectal Cancer Location May Influence Survival
By HospiMedica International staff writers Posted on 11 Mar 2015 |
The primary tumor location of metastatic colorectal cancer (mCRC) has prognostic impact on survival, according to a new study.
Researchers at the University of Southern California (Los Angeles, USA) and Azienda Ospedaliero-Universitaria Pisana (Pisa, Italy), and other institutions reviewed three studies involving 2,027 patients with previously untreated mCRC to evaluate the association between tumor location and survival parameters. The researchers used data from a prospective pharmacogenetic study and two randomized phase III trials. The primary end point was overall survival, with progression-free survival assessed according to tumor location, i.e., proximal or distal of the splenic flexure.
The results showed that over the three studies, about 70% of patients had left-sided primary tumors and had better survival outcomes than those with right-sided tumors. In one study, right-sided tumor location also had a negative prognostic value independent of BRAF mutation status or histological type. The researchers found that efficacy of bevacizumab was independent of tumor location, but right-sided tumors were associated with development of chemoresistance, hinting at biological differences. The study was published in the February 25, 2015, issue of JNCI: Journal of the National Cancer Institute.
“The two halves of the human colon have different embryonic origins and gene expression patterns, and these differences may also play a role in cancer biology,” concluded lead author Fotios Loupakis, MD, PhD, of the USC Norris Comprehensive Cancer Center, and colleagues. “Given the consistency across an exploratory set and two confirmatory phase III studies, side of tumor origin should be considered for stratification in randomized trials.”
Colorectal cancer is the development of cancer in the large intestine. Most deaths due to colon cancer are associated with mCRC (stage IV colorectal cancer). Cure is not possible for most patients with mCRC, although some patients who have limited involvement of distant organs (particularly restricted to the liver and/or lung) can be cured with surgery. For others, chemotherapy is the most appropriate option. Chemotherapy does not cure mCRC, but it can improve symptoms and prolong life.
Related Links:
University of Southern California
Azienda Ospedaliero-Universitaria Pisana
Researchers at the University of Southern California (Los Angeles, USA) and Azienda Ospedaliero-Universitaria Pisana (Pisa, Italy), and other institutions reviewed three studies involving 2,027 patients with previously untreated mCRC to evaluate the association between tumor location and survival parameters. The researchers used data from a prospective pharmacogenetic study and two randomized phase III trials. The primary end point was overall survival, with progression-free survival assessed according to tumor location, i.e., proximal or distal of the splenic flexure.
The results showed that over the three studies, about 70% of patients had left-sided primary tumors and had better survival outcomes than those with right-sided tumors. In one study, right-sided tumor location also had a negative prognostic value independent of BRAF mutation status or histological type. The researchers found that efficacy of bevacizumab was independent of tumor location, but right-sided tumors were associated with development of chemoresistance, hinting at biological differences. The study was published in the February 25, 2015, issue of JNCI: Journal of the National Cancer Institute.
“The two halves of the human colon have different embryonic origins and gene expression patterns, and these differences may also play a role in cancer biology,” concluded lead author Fotios Loupakis, MD, PhD, of the USC Norris Comprehensive Cancer Center, and colleagues. “Given the consistency across an exploratory set and two confirmatory phase III studies, side of tumor origin should be considered for stratification in randomized trials.”
Colorectal cancer is the development of cancer in the large intestine. Most deaths due to colon cancer are associated with mCRC (stage IV colorectal cancer). Cure is not possible for most patients with mCRC, although some patients who have limited involvement of distant organs (particularly restricted to the liver and/or lung) can be cured with surgery. For others, chemotherapy is the most appropriate option. Chemotherapy does not cure mCRC, but it can improve symptoms and prolong life.
Related Links:
University of Southern California
Azienda Ospedaliero-Universitaria Pisana
Latest Surgical Techniques News
- Miniaturized Snake-Like Probe Images Cerebral Arteries From Within
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing